Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries 
SaunaKits.com Opens Its Upstate South Carolina Showroom, Bringing Hands-On Sauna Shopping to the Southeast 
Encore Construction Shares Guidance to Help Homeowners Avoid Costly Water Damage Insurance Claim Mistakes Allen Matkins Expands its Land Use Practice with Addition of Partner Jonathan E. Shardlow to its Orange County Office
IRVINE, Calif.–(BUSINESS WIRE)–Allen Matkins, a California-based, full-service real estate and business law firm, announced today…
iCapital® Expands Strategic Partnership With Bank of Singapore
Deal deepens iCapital’s relationship with one of the fastest growing Asian private banks and accelerates…
Cosmos Holdings Announces Closing of $6 Million Private Placement of Convertible Preferred Stock and Start of Trading on the Nasdaq
CHICAGO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Cosmos Holdings, Inc. (“the Company”) (Nasdaq: COSM), an…
Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected…
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021
Cash and cash equivalents totaled €258.8 million as of December 31, 2021, which includes the…
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
— First Participants Dosed in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of…
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two…
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and…
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Provides 10-year market exclusivity in EU upon regulatory approval DEVON, Pa., Feb. 28, 2022 (GLOBE…
Day One to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN),…
Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company…
Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago”) (Nasdaq:…
Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook
Demonstrated tangible market progress and shipped 17 instruments through year end 2021 REDWOOD CITY, Calif.,…
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4…
Berkeley Lights to Participate in Cowen 42nd Annual Health Care Conference
EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader…
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing…
Angion Announces Participation in Upcoming Investment Conferences
UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company…
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Generated $15.1 million in full year 2021 EMPAVELI® (pegcetacoplan) net product revenues; demonstrated strong initial…